Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
4 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-4 of 4
Optogenetic protein clustering is a light-controlled engineering method reported in mammalian cells to induce protein clustering and activate signaling. The available evidence identifies it as an optogenetic approach for regulating signaling with light input.
CRY2clust is an engineered CRY2-based optogenetic module that drives blue light-dependent homo-oligomerization and clustering of fused target proteins. It was reported as a new CRY2 variant that enables rapid and efficient protein clustering with spatiotemporal optical control.
The light-controlled optogenetic CD3ζ clustering tool is a multi-component optogenetic system engineered to induce spatial clustering of CD3ζ chains with light. In the cited 2020 study, light-driven CD3ζ clustering was sufficient to initiate proximal T cell receptor signaling, including CD3ζ phosphorylation and recruitment of the tandem SH2 domain of Zap70 to plasma membrane clusters.
The light-inducible protein aggregation (LIPA) system is a light-controlled multi-component switch developed to enable spatiotemporal control of α-synuclein aggregation. It is described as a tool for inducing α-synuclein aggregation into insoluble deposits called Lewy bodies for in vivo analysis in Parkinson disease contexts.